A Phase I/II Study of the Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma
Latest Information Update: 13 May 2022
At a glance
- Drugs Lenalidomide (Primary) ; Pembrolizumab (Primary)
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 12 Aug 2020 Status changed from completed to discontinued.
- 05 Jun 2020 Status changed from active, no longer recruiting to completed.
- 05 Jun 2018 Status changed from recruiting to active, no longer recruiting.